Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
NW Suite 240 Salem, OR 97304 Get Directions South Salem Clinic 1610 12th St
Every human cohort ever dosed with this molecule received it into or onto its target: intra-articular into the knee, intravesical into the bladder wall, rectal enema onto colonic mucosa
Reported Adverse Effects In the available case series and observational literature, the most commonly reported adverse effects include: Injection-site redness or mild induration in approximately 8 to 12% of users Transient nausea, most often associated with oral formulations or higher injectable doses Lightheadedness in a small number of patients shortly after injection (under 2% of reported cases) Vivid dreams or mild sleep changes, reported anecdotally by a subset of users with no clear mechanistic explanation No published human case reports as of July 2025 document serious organ toxicity, malignancy, or endocrine disruption attributable to BPC-157
The peptides sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) was first characterized by research groups investigating cytoprotective properties of gastric juice-derived compounds
At this stage, it is worth exercising extreme caution - rather, the peptide should be allowed to dissolve in water on its own, and certainly should not be shaken vigorously
Missed doses during the loading phase are the usual reason a stall shows up in weeks 35
